CAPLYTA proven to be as a promising option for achieving remission in adults with major depressive disorder

Johnson & Johnson has recentlt announced their new analysis of Phase 3 data which found CAPLYTA in combination with an antidepressant, showed significantly greater remission rates in adults with major depressive disorder than placebo plus an antidepressant at six weeks, with continued benefits observed through six months in an open-label extension study.

Note that MDD is a common psychiatric disorders, affecting about 22 million American adults. While remission relief from depressive symptoms – is the ultimate goal of treatment, nearly two-thirds of patients do not achieve it with available therapies. Patients with residual symptoms experience prolonged psychosocial impairment, higher relapse risk and overall reduced quality of life.

“Today, remission is out of reach for the majority of patients with depression, which means they continue to struggle with persistent symptoms that negatively impact their daily lives,” said Michael E. Thase, M.D., Professor of Psychiatry and Chief, Division of Mood and Anxiety Disorders Treatment & Research Program, Perelman School of Medicine at University of Pennsylvania. “These data capture not only symptom reduction, but also the durability and depth of treatment response, which are critical benchmarks for patients and clinicians striving for lasting relief. The findings demonstrate that adjunctive lumateperone may almost double the likelihood of remission, with benefits sustained over six months, offering renewed hope to millions of adults seeking recovery from this disease.”

---

---

Related Topics and Keywords

caplyta, Depressive Disorder, Johnson and Johnson, lumateperone